Quarry LP’s Blueprint Medicines BPMC Stock Holding History

Quarry LP’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-350	Closed	-$32.4K	–	1650
2024 Q3	$32.4K	Buy	+350	New	+$34.8K	0.01%	931

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Quarry LP's BPMC Position: Q4 2024 in Review

Quarry LP sold out of Blueprint Medicines (BPMC) in Q4 2024, closing a stake of 350 shares — an estimated $32.4K sold.

Quarry LP first reported a position in BPMC in Q3 2024 and held it in 1 quarter. The position peaked at $32.4K in Q3 2024. 345 funds tracked by Wall St. Rank hold BPMC as of Q4 2024.

Quarry LP reported no remaining Blueprint Medicines position as of Q4 2024 after selling out during the quarter.
Quarry LP sold 350 Blueprint Medicines shares in Q4 2024, an estimated $32.4K.
Quarry LP first reported a position in Blueprint Medicines in Q3 2024 and held it in 1 quarter.
Quarry LP's Blueprint Medicines position peaked at $32.4K in Q3 2024.
345 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2024.

Based on Quarry LP's 13F filing for Q4 2024, filed 14 Feb 2025.